Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-185 in newly diagnosed untreated multiple myeloma
MOH_2017-01-03_000009Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of pembrolizumab, lenalidomide and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by Merck & Co. Primary endpoint: Not reported in registry entry. Started Oct 2015; status: completed.
02
Drugs
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on MOH_2017-01-03_000009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-01-03_000009.